Marika Lassila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marika Lassila has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fatemeh Seyednasrollah
Translational Cancer Medicine Program, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland
17 shared publications - Kari Alitalo
Wihuri Research Institute and Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
17 shared publications - Pauliina Kallio
Translational Cancer Medicine Program, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland
17 shared publications - Tatiana V. Petrova
University of Lausanne
17 shared publications - Alejandra González-Loyola
Ludwig Institute for Cancer Research Lausanne, University of Lausanne 1 Department of Fundamental Oncology Epalinges
16 shared publications - Caj Haglund
University of Helsinki
16 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eaeb8564
Progressive intestinal tumor cell plasticity, Myc activation, and loss of Lgr5 + tumor stem cell lineage commitment upon Wnt depletion
Plasticity, the capability of tumor cells to go through phenotypic transitions, promotes colorectal cancer (CRC) progression and treatment resistance. Although plasticity is evident in advanced CRCs, little is known about plasticity in early-stage tumors and tumor stem cells. Here, we demonstrate that a plastic cell state (PCS) is present already in polyps from patients with familial adenomatous polyposis and in mouse intestinal adenomas, in which PCS is associated with PROX1 + tumor stem cells. We furthermore analyzed progressive plasticity upon loss of the canonical wingless-related integration site (Wnt) effector Tcf7 or Lef1 in Apc mutant mice. Deletion of either gene led to emergence of new plastic tumor cell populations, failure of leucine-rich repeat–containing G protein-coupled receptor 5 (Lgr5) tumor stem cell differentiation into enterocyte-like cells, enhanced Myc pathway activation, and increased tumor cell proliferation and tumorigenesis. Together, we demonstrate that PCS is associated with early CRC development and identify multiple potentially druggable mechanisms activated during progressive tumor cell plasticity.
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eaeb8564
Open AccessProgressive intestinal tumor cell plasticity, Myc activation, and loss of Lgr5 + tumor stem cell lineage commitment upon Wnt depletion
Plasticity, the capability of tumor cells to go through phenotypic transitions, promotes colorectal cancer (CRC) progression and treatment resistance. Although plasticity is evident in advanced CRCs, little is known about plasticity in early-stage tumors and tumor stem cells. Here, we demonstrate that a plastic cell state (PCS) is present already in polyps from patients with familial adenomatous polyposis and in mouse intestinal adenomas, in which PCS is associated with PROX1 + tumor stem cells. We furthermore analyzed progressive plasticity upon loss of the canonical wingless-related integration site (Wnt) effector Tcf7 or Lef1 in Apc mutant mice. Deletion of either gene led to emergence of new plastic tumor cell populations, failure of leucine-rich repeat–containing G protein-coupled receptor 5 (Lgr5) tumor stem cell differentiation into enterocyte-like cells, enhanced Myc pathway activation, and increased tumor cell proliferation and tumorigenesis. Together, we demonstrate that PCS is associated with early CRC development and identify multiple potentially druggable mechanisms activated during progressive tumor cell plasticity.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S9
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S9
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S1
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S1
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S5
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S5
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Data from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
Colorectal cancer progression is associated with an increase in PROX1+ tumor cells, which exhibit features of colorectal cancer stem cells and contribute to metastasis. Here, we aimed to provide a better understanding of the function of PROX1+ cells in colorectal cancer, investigating their progeny and their role in therapy resistance. PROX1+ cells in intestinal adenomas of ApcMin/+ mice expressed intestinal epithelial and colorectal cancer stem cell markers, and cells with high PROX1 expression could both self-renew tumor stem/progenitor cells and contribute to differentiated tumor cells. Most Prox1 lineage–traced tumor cells were stem/progenitor cells, which can supply cells to multiple intestinal tumor cell lineages, whereas most lineage-traced Lgr5+ tumor cells were enterocytes, indicating that Prox1+ and Lgr5+ tumor stem cells have distinct differentiation programs. Although the PROX1+ tumor cells proliferated slower than PROX1− cells, irradiation increased the proportion of PROX1+ cells in human colorectal cancer cell lines, patient-derived organoids, and tumor xenografts. Furthermore, transcripts related to DNA damage repair (DDR) were enriched in PROX1+ versus PROX1− cells in adenomas and in colorectal cancer tumor cells from patients. Experiments with PROX1 silencing and overexpression indicated that PROX1 expression enhances colorectal cancer cell colony formation following irradiation. PROX1 interacted with DDR proteins, including components of nonhomologous end joining (NHEJ) and base excision repair, and inhibition of NHEJ repair led to a decreased proportion of PROX1+ cells following irradiation. In conclusion, PROX1+ cells are irradiation-resistant tumor stem/progenitor cells capable of self-renewal and differentiation. DDR inhibitors could represent a strategy to target the treatment-resistant PROX1+ tumor stem cells.Significance:Colorectal cancer stem/progenitor cells expressing the PROX1 transcription factor display increased radiation resistance, which may be targeted by small-molecule inhibitors of the nonhomologous end-joining DNA damage repair pathway.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
Colorectal cancer progression is associated with an increase in PROX1+ tumor cells, which exhibit features of colorectal cancer stem cells and contribute to metastasis. Here, we aimed to provide a better understanding of the function of PROX1+ cells in colorectal cancer, investigating their progeny and their role in therapy resistance. PROX1+ cells in intestinal adenomas of ApcMin/+ mice expressed intestinal epithelial and colorectal cancer stem cell markers, and cells with high PROX1 expression could both self-renew tumor stem/progenitor cells and contribute to differentiated tumor cells. Most Prox1 lineage–traced tumor cells were stem/progenitor cells, which can supply cells to multiple intestinal tumor cell lineages, whereas most lineage-traced Lgr5+ tumor cells were enterocytes, indicating that Prox1+ and Lgr5+ tumor stem cells have distinct differentiation programs. Although the PROX1+ tumor cells proliferated slower than PROX1− cells, irradiation increased the proportion of PROX1+ cells in human colorectal cancer cell lines, patient-derived organoids, and tumor xenografts. Furthermore, transcripts related to DNA damage repair (DDR) were enriched in PROX1+ versus PROX1− cells in adenomas and in colorectal cancer tumor cells from patients. Experiments with PROX1 silencing and overexpression indicated that PROX1 expression enhances colorectal cancer cell colony formation following irradiation. PROX1 interacted with DDR proteins, including components of nonhomologous end joining (NHEJ) and base excision repair, and inhibition of NHEJ repair led to a decreased proportion of PROX1+ cells following irradiation. In conclusion, PROX1+ cells are irradiation-resistant tumor stem/progenitor cells capable of self-renewal and differentiation. DDR inhibitors could represent a strategy to target the treatment-resistant PROX1+ tumor stem cells.Significance:Colorectal cancer stem/progenitor cells expressing the PROX1 transcription factor display increased radiation resistance, which may be targeted by small-molecule inhibitors of the nonhomologous end-joining DNA damage repair pathway.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S2
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S2
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF containing updated Supplementary Figure S10
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF containing updated Supplementary Figure S10
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
Supplementary Table S1 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
Supplementary Table S1 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S11
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S11
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S6
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
PDF file containing Supplementary Figure S6